Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16321536 | 0.81 | IDO1 (0.44) | RAB9AIDO1MAPTGAAPKM | |
| SCHEMBL4051675 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AIDO1MAPK1 | |
| SCHEMBL6046573 | 0.77 | MAPT (0.43) | SMN1; SMN2NPC1RAB9AIDO1MAPK1 | |
| SCHEMBL12054424 | 0.75 | KMT2A (0.48) | SMN1; SMN2NPC1RAB9AMAPK1KMT2A | |
| SCHEMBL14693884 | 0.74 | IDO1 (0.53) | NPC1RAB9AIDO1MAPTPKM | |
| SCHEMBL16321109 | 0.72 | IDO1 (0.42) | RAB9AIDO1MAPTPKMKMT2A | |
| SCHEMBL6046615 | 0.71 | GAA (0.42) | RAB9AIDO1MAPTGAAPKM | |
| SCHEMBL19812520 | 0.70 | KMT2A (0.39) | SMN1; SMN2NPC1RAB9AIDO1MAPT | |
| SCHEMBL17595973 | 0.70 | MAPT (0.41) | SMN1; SMN2RAB9AIDO1MAPTGAA | |
| SCHEMBL16321277 | 0.69 | IDO1 (0.39) | RAB9AIDO1MAPTGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | claimed |
| EP-1879573-B1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORP (US) | 2012-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | SMN1; SMN2 4675/4885NPC1 4033/4885RAB9A 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.